Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Spironolactone

    Menu

    Spironolactone

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Actinium pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the T...

              Details:

              Under the terms of the CRADA, the NCI will serve as sponsor for any clinical trials mutually approved by both parties to study Actimab-A (lintuzumab-Ac225) while Actinium will be responsible for supplying and distributing Actimab-A.

              Lead Product(s): Lintuzumab-ac225,Spironolactone

              Therapeutic Area: Oncology Product Name: Actimab-A

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: National Cancer Institute

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              EUROAPI Spironolactone
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY